Abstract
GlaxoSmithKline and Ligand are developing GW-501516, a peroxisome proliferator-activator receptor-delta agonist for the potential treatment of dyslipidemia. Phase II clinical trials of this compound are ongoing.
MeSH terms
-
Animals
-
Fatty Acids / metabolism
-
Glucose / metabolism
-
Humans
-
Hypolipidemic Agents / pharmacology*
-
Macaca mulatta
-
Mice
-
Mice, Obese
-
PPAR delta / drug effects
-
PPAR delta / physiology
-
Structure-Activity Relationship
-
Thiazoles / chemical synthesis
-
Thiazoles / pharmacology*
-
Thiazoles / therapeutic use
Substances
-
Fatty Acids
-
GW 501516
-
Hypolipidemic Agents
-
PPAR delta
-
Thiazoles
-
Glucose